Leerink Partners Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $170

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Leerink Partners analyst Marc Goodman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $160 to $170.